148 related articles for article (PubMed ID: 8021814)
1. Effect of MTP-PE liposomes and interleukin-7 on induction of antibody and cell-mediated immune responses to a recombinant HIV-envelope protein.
Bui T; Dykers T; Hu SL; Faltynek CR; Ho RJ
J Acquir Immune Defic Syndr (1988); 1994 Aug; 7(8):799-806. PubMed ID: 8021814
[TBL] [Abstract][Full Text] [Related]
2. Clinical and immunologic responses to human immunodeficiency virus (HIV) type 1SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers.
Kahn JO; Sinangil F; Baenziger J; Murcar N; Wynne D; Coleman RL; Steimer KS; Dekker CL; Chernoff D
J Infect Dis; 1994 Nov; 170(5):1288-91. PubMed ID: 7963729
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group.
Keefer MC; Graham BS; McElrath MJ; Matthews TJ; Stablein DM; Corey L; Wright PF; Lawrence D; Fast PE; Weinhold K; Hsieh RH; Chernoff D; Dekker C; Dolin R
AIDS Res Hum Retroviruses; 1996 May; 12(8):683-93. PubMed ID: 8744579
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxic T lymphocyte and antibody responses generated in rhesus monkeys immunized with retroviral vector-transduced fibroblasts expressing human immunodeficiency virus type-1 IIIB ENV/REV proteins.
Laube LS; Burrascano M; Dejesus CE; Howard BD; Johnson MA; Lee WT; Lynn AE; Peters G; Ronlov GS; Townsend KS
Hum Gene Ther; 1994 Jul; 5(7):853-62. PubMed ID: 7981310
[TBL] [Abstract][Full Text] [Related]
5. Liposomes containing muramyl tripeptide phosphatidylethanolamine (MTP-PE) are excellent adjuvants for induction of an immune response to protein and tumor antigens.
Ullrich SE; Fidler IJ
J Leukoc Biol; 1992 Nov; 52(5):489-94. PubMed ID: 1431559
[TBL] [Abstract][Full Text] [Related]
6. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
[TBL] [Abstract][Full Text] [Related]
7. Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine.
Wu JY; Gardner BH; Murphy CI; Seals JR; Kensil CR; Recchia J; Beltz GA; Newman GW; Newman MJ
J Immunol; 1992 Mar; 148(5):1519-25. PubMed ID: 1538134
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of a genetically engineered human immunodeficiency virus vaccine.
Wintsch J; Chaignat CL; Braun DG; Jeannet M; Stalder H; Abrignani S; Montagna D; Clavijo F; Moret P; Dayer JM
J Infect Dis; 1991 Feb; 163(2):219-25. PubMed ID: 1988506
[TBL] [Abstract][Full Text] [Related]
9. Eliciting HIV-1 envelope-specific antibodies with mixed vaccinia virus recombinants.
Rencher SD; Lockey TD; Srinivas RV; Owens RJ; Hurwitz JL
Vaccine; 1997 Feb; 15(3):265-72. PubMed ID: 9139484
[TBL] [Abstract][Full Text] [Related]
10. Resistance to human immunodeficiency virus 1 infection of SCID mice reconstituted with peripheral blood leukocytes from donors vaccinated with vaccinia gp160 and recombinant gp160.
Mosier DE; Gulizia RJ; MacIsaac PD; Corey L; Greenberg PD
Proc Natl Acad Sci U S A; 1993 Mar; 90(6):2443-7. PubMed ID: 8460155
[TBL] [Abstract][Full Text] [Related]
11. Anti-HIV env immunities elicited by nucleic acid vaccines.
Shiver JW; Davies ME; Yasutomi Y; Perry HC; Freed DC; Letvin NL; Liu MA
Vaccine; 1997 Jun; 15(8):884-7. PubMed ID: 9234539
[TBL] [Abstract][Full Text] [Related]
12. Effect of ibuprofen on monocyte activation by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (CGP 19835A): can ibuprofen reduce fever and chills without compromising immune stimulation?
Fujimaki W; Griffin JR; Kleinerman ES
Cancer Immunol Immunother; 1993; 36(1):45-51. PubMed ID: 8422667
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic T lymphocyte and helper T cell responses following HIV polynucleotide vaccination.
Shiver JW; Perry HC; Davies ME; Freed DC; Liu MA
Ann N Y Acad Sci; 1995 Nov; 772():198-208. PubMed ID: 8546393
[TBL] [Abstract][Full Text] [Related]
14. Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120.
AIDS Vaccine Evaluation Group 022 Protocol Team
J Infect Dis; 2001 Feb; 183(4):563-70. PubMed ID: 11170981
[TBL] [Abstract][Full Text] [Related]
15. Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies.
Deml L; Schirmbeck R; Reimann J; Wolf H; Wagner R
Virology; 1997 Aug; 235(1):26-39. PubMed ID: 9300034
[TBL] [Abstract][Full Text] [Related]
16. Increased level and longevity of protective immune responses induced by DNA vaccine expressing the HIV-1 Env glycoprotein when combined with IL-21 and IL-15 gene delivery.
Bolesta E; Kowalczyk A; Wierzbicki A; Eppolito C; Kaneko Y; Takiguchi M; Stamatatos L; Shrikant PA; Kozbor D
J Immunol; 2006 Jul; 177(1):177-91. PubMed ID: 16785513
[TBL] [Abstract][Full Text] [Related]
17. A vaccinia-gp160-based vaccine but not a gp160 protein vaccine elicits anti-gp160 cytotoxic T lymphocytes in some HIV-1 seronegative vaccinees.
Perales MA; Schwartz DH; Fabry JA; Lieberman J
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Sep; 10(1):27-35. PubMed ID: 7648281
[TBL] [Abstract][Full Text] [Related]
18. IL-12 delivery from recombinant vaccinia virus attenuates the vector and enhances the cellular immune response against HIV-1 Env in a dose-dependent manner.
Gherardi MM; Ramirez JC; Rodríguez D; Rodríguez JR; Sano G; Zavala F; Esteban M
J Immunol; 1999 Jun; 162(11):6724-33. PubMed ID: 10352291
[TBL] [Abstract][Full Text] [Related]
19. Targeting of HIV-1 antigens for rapid intracellular degradation enhances cytotoxic T lymphocyte (CTL) recognition and the induction of de novo CTL responses in vivo after immunization.
Tobery TW; Siliciano RF
J Exp Med; 1997 Mar; 185(5):909-20. PubMed ID: 9120397
[TBL] [Abstract][Full Text] [Related]
20. Studies on in vivo induction of HIV-1 envelope-specific cytotoxic T lymphocytes by synthetic peptides from the V3 loop region of HIV-1 IIIB gp 120.
Nehete PN; Casement KS; Arlinghaus RB; Sastry KJ
Cell Immunol; 1995 Feb; 160(2):217-23. PubMed ID: 7720083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
